Idh Mutant Grade 2 Or 3 Astrocytoma clinical trials

Explore recruiting idh mutant grade 2 or 3 astrocytoma clinical trials.

Recruiting idh mutant grade 2 or 3 astrocytoma studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Idh Mutant Grade 2 Or 3 Astrocytoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)

Germany, France, Italy, Austria, Netherlands, Spain +2 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Idh Mutant Grade 2 Or 3 Astrocytoma trials by city

Idh Mutant Grade 2 Or 3 Astrocytoma clinical trials

Recruiting idh mutant grade 2 or 3 astrocytoma studies right now

Vorasidenib Maintenance for IDH Mutant Astrocytoma

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma

Also recruiting in Europe

EORTC-2427-BTG: Vorasidenib as maintenance treatment after first-line chemoradiotherapy in IDH-mutant grade 2 or 3 astrocytoma: a placebo-controlled, triple-blind, randomized phase III study (VIGOR)

Idh Mutant Grade 2 Or 3 Astrocytoma trials by city

Other conditions